In this article
Lung Cancer Treatment at Shanghai Pulmonary Hospital – A patient story
In April 2025, Shanghai Pulmonary Hospital welcomed a special patient, Ms. Dietrich from the United States. In 2024, doctors diagnosed Ms. Dietrich with advanced non-small cell lung cancer (NSCLC) featuring the rare “EGFR 20-exon insertion mutation” (EGFR 20ins), and she had exhausted treatment options in multiple countries. Her journey to China marked a pivotal moment in her fight against cancer, highlighting the hospital’s global reputation for excellence in treating complex lung conditions.
In the United States, Ms. Dietrich underwent a combination of chemotherapy and treatment with Amivantamab, a bispecific antibody targeting EGFR 20ins. However, the treatment’s efficacy was limited, and she developed drug resistance over time. While researching the latest global medical advancements, she discovered that Shanghai Pulmonary Hospital had made significant breakthroughs in EGFR 20ins treatment. Impressed by the hospital’s achievements, she reached out to Professor Ren Shengxiang, Director of the Oncology Department, via email and scheduled an appointment.
Multidisciplinary Approach and Personalized Treatment Plan
Upon receiving Ms. Dietrich’s request, Professor Ren and his team immediately assembled a multidisciplinary team to discuss her case. Since traditional treatments weren’t working well, the team first suggested trying Sunvozertinib, a new type of drug made in China that targets a specific problem, but they wanted to evaluate her in person first.
On the day of her consultation, Professor Ren’s team efficiently completed a comprehensive series of examinations, including face-to-face consultations, CT scans, and blood tests. Based on the results of Ms. Dietrich’s genetic testing and other examinations, the team finalized a treatment plan centered around oral administration of Sunvozertinib, a cutting-edge, Chinese-developed targeted drug.
Shanghai Pulmonary Hospital’s Oncology Department has been at the forefront of clinical research on NSCLC with EGFR 20ins. The department has led numerous national and global multicenter Phase III clinical trials involving drugs such as Mobocertinib, Amivantamab, and Sunvozertinib. Their research findings have been published in top international medical journals, including The New England Journal of Medicine and The Lancet Oncology.
Additionally, the department has played a leading role in formulating the Expert Consensus on the Diagnosis and Treatment of NSCLC with EGFR 20ins, providing effective treatment options and extending the survival time of patients worldwide. This progress from “Chinese-developed new drugs” to “Chinese-speed innovation” demonstrates the hospital’s rapid advancement towards becoming a world-class clinical center for pulmonary diseases.
After a course of treatment following the hospital’s protocol, Ms. Dietrich’s comprehensive assessment showed remarkable results. All her lesions significantly shrank, and some even disappeared completely. She was deeply impressed by the convenience of China’s medical services and the professionalism and authority of Shanghai Pulmonary Hospital in lung cancer treatment.
Ms. Dietrich expressed her gratitude to Professor Ren, expressing her hope that this “Chinese treatment plan” could serve as a guiding light for patients worldwide, spreading hope and benefiting more individuals facing similar challenges.
This case not only showcases the effectiveness of Chinese-developed drugs and the high-quality medical services provided by Shanghai Pulmonary Hospital but also underscores China’s growing influence in global oncology research and treatment. As the hospital continues to push the boundaries of medical science, it is opening new doors of hope for patients globally, reaffirming its commitment to improving healthcare on an international scale.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.